Pharmasset Announces Clevudine And R7128 Presentations At HEP DART

Pharmasset, Inc. (Nasdaq: VRUS) announces that interim results of physician-sponsored studies of clevudine for the treatment of chronic hepatitis B virus (HBV) and both preclinical and clinical results of R7128 for the treatment of chronic hepatitis C virus (HCV) will be presented at the Frontiers in Drug Development in Viral Hepatitis (HEP-DART) conference being held in Lahaina, Hawaii from December 9 - 13, 2007. [click link for full article]

More: continued here

Filed under: Clinical Trials on December 15th, 2007